The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial
Abstract
To report long‐term results of a randomized controlled trial that compared cisplatin/fluorouracil/docetaxel (TPF) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with stage III–IVB (except T3–4 N0) NPC were randomly assigned to receive IC plus CCRT (n = 241) or CCRT alone (n = 239). IC included three cycles of docetaxel (60 mg/m 2 d1), cisplatin (60 mg/m 2 d1), and fluorouracil (600 mg/m 2/d civ d1–5) every 3 weeks. Patients from both groups received intensity‐modulated radiotherapy concurrently with three cycles of 100 mg/m 2 cisplatin every 3 weeks. After a median follow‐up of 71.5 months, the IC plus CCRT group showed significantly better 5‐year failure‐free survival (FFS, 77.4%vs. 66.4%,p= 0.019), overall survival (OS, 85.6%vs. 77.7%,p= 0.042), distant failure‐free survival (88%vs. 79.8%,p= 0.030), and locoregional failure‐free survival (90.7%vs. 83.8%,p= 0.044) compared to the CCRT alone group.Post hoc subgroup analyses revealed that beneficial effects on FFS were primarily observed in patients with N1, stage IVA, pretreatment lactate dehydrogenase ≥170 U/l, or pretreatment plasma Epstein–Barr virus DNA ≥6000 copies/mL. Two nomograms were further developed to predict the potential FFS and OS benefit of TPF IC. The incidence of grade 3 or 4 late toxicities was 8.8% (21/239) in the IC plus CCRT group and 9.2% (22/238) in the CCRT alone group. Long‐term follow‐up confirmed that TPF IC plus CCRT significantly improved survival in locoregionally advanced NPC with no marked increase in late toxicities and could be an option of treatment for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationGemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905287 · Cited by 927
Self-citationNasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Self-citationTang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Self-citationChen, Y.-P., Ismaila, N., Chua, M. L. K., Colevas, A. D., Haddad, R., Huang, S. H., Wee, J. T. S., Whitley, A. C., Yi, J.-L., Yom, S. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03237 · Cited by 390
Self-citation
Metadata
- Authors
- Li, W., Chen, N., Zhang, N., Hu, G., Xie, F., Sun, Y., Chen, X., Li, J., Zhu, X., Hu, C., Xu, X., Chen, Y., Hu, W., Guo, L., Mo, H., Chen, L., Mao, Y., Sun, R., Ai, P., Liang, S., Long, G., Zheng, B., Feng, X., Gong, X., Li, L., Shen, C., Xu, J., Guo, Y., Chen, Y., Zhang, F., Lin, L., Tang, L., Liu, M., Ma, J., & Sun, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-01-24
- Volume
- 145
- Issue
- 1
- Pages
- 295-305
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2909326374
- Cited by
- 251
- References
- 1
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.